# Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

> **NCT06361316** · NA · RECRUITING · sponsor: **Kuirong Jiang** · enrollment: 53 (estimated)

## Conditions studied

- Pancreatic Cancer
- Adjuvant Therapy

## Interventions

- **DRUG:** Irinotecan liposome injection

## Key facts

- **NCT ID:** NCT06361316
- **Lead sponsor:** Kuirong Jiang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2025-03-25
- **Final completion:** 2028-07-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361316, "Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06361316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*